Alexion Pharmaceuticals Archives - Corruption, Crime & Compliance

10 Jul, 2020

Alexion FCPA Violations: Lessons Learned (Part II of II)

The Alexion Pharmaceutical SEC FCPA enforcement action represents another in the long line of enforcement actions against drug and device companies. The drug and device industries have been – and will continue to be — easy marks for prosecutors to investigate and prosecute for foreign bribery. There are a number of reason for this. First, global drug and device depend on interactions with foreign healthcare...

General

8 Jul, 2020

Alexion Pays SEC $21 Million for FCPA Violations (Part I of II)

Notwithstanding the pandemic and remote working arrangements, the Securities and Exchange Commission is continuing to bring FCPA enforcement actions. In its latest action, the SEC settled with Alexion Pharmaceuticals for $21 million for foreign bribery and books and records violations. Alexion is a global pharmaceutical company. Its first drug, Soliris was approved to treat two ultra-rare diseases, paroxysmal nocturnal hemoglobinuria (“PNH”), which causes red blood...